NCT01922154

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Siriraj Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).

Detailed description

This is a prospective study of 15 consecutive eyes from 14 patients (One patients had NVG in both eyes at presentation.) with NVG presented at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand between December 2008 and December 2009. Each eye received IVR (0.5 mg/0.05 ml) 1 week before TMC. Trabeculectomy was performed with fornix-based conjunctival flap method.

Conditions

• Glaucoma, Neovascular

Interventions

Type	Name	Description
DRUG	intravitreal ranibizumab	The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
PROCEDURE	Trabeculectomy with mitomycinC	All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.

Timeline

• Start date: 2009-02-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2013-08-14
• Last updated: 2021-07-16

Locations

1 site across 1 country: Thailand